What's the outlook for PTGX's Q4 2024 earnings?

**Protagonist Therapeutics Inc. (PTGX) is likely to report earnings per share (EPS) of approximately $0.06 for Q4 2024**, based on the latest estimates available. This outlook is supported by the following points: 1. **Analyst Expectations**: The estimated EPS of $0.06 for Q4 2024 is based on analysts' expectations. This is a significant improvement from the previous quarter's adjusted loss of $0.54 per share, indicating a potential recovery or improvement in the company's financial performance. 2. **Comparative Analysis**: When compared to the same quarter last year, the EPS of $0.06 for Q4 2024 represents a substantial improvement. In the corresponding quarter of the previous year, the company reported an EPS of -$0.58. This suggests that Q4 2024 could be a strong rebound period for the company. 3. **Revenue Considerations**: While specific revenue estimates for Q4 2024 are not available, the company has previously reported revenue that exceeded estimates in another quarter. This indicates a potential for strong revenue generation, which could support the positive earnings outlook. 4. **Market Sentiment and Transactions**: Recent transactions involving the company, such as the purchase of 26,280 shares by Inspire Investing LLC, and the company's market capitalization of $2.70 billion, suggest a level of market confidence that could positively influence earnings expectations. 5. **Strategic Developments**: Protagonist Therapeutics has made significant progress in its pipeline, including the development of rusfertide and its IL-17 Peptide Antagonist Program. These developments could potentially lead to future revenue streams and support the company's financial outlook. In conclusion, the outlook for PTGX's Q4 2024 earnings appears positive, with the potential for significant improvement in EPS compared to the previous quarter. However, investors should monitor the company's revenue figures and ongoing pipeline developments for a more comprehensive understanding of its financial health and future prospects.